Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.

MLA

Sands, Bruce E., et al. “Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.” The New England Journal of Medicine, vol. 391, no. 12, Sept. 2024, pp. 1119–29. EBSCOhost, https://doi.org/10.1056/NEJMoa2314076.

APA

Sands, B. E., Feagan, B. G., Peyrin-Biroulet, L., Danese, S., Rubin, D. T., Laurent, O., Luo, A., Nguyen, D. D., Lu, J., Yen, M., Leszczyszyn, J., Kempiński, R., McGovern, D. P. B., Ma, C., Ritter, T. E., & Targan, S. (2024). Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. The New England Journal of Medicine, 391(12), 1119–1129. https://doi.org/10.1056/NEJMoa2314076

Chicago

Sands, Bruce E, Brian G Feagan, Laurent Peyrin-Biroulet, Silvio Danese, David T Rubin, Olivier Laurent, Allison Luo, et al. 2024. “Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.” The New England Journal of Medicine 391 (12): 1119–29. doi:10.1056/NEJMoa2314076.